Scarica l'app Stockscreener
14.75
14.94%
-2.59
Pre-mercato:
14.70
-0.05
-0.34%
Precedente Chiudi:
$17.34
Aprire:
$16.12
Volume 24 ore:
85,061
Relative Volume:
0.99
Capitalizzazione di mercato:
$138.49M
Reddito:
-
Utile/perdita netta:
$-81.17M
Rapporto P/E:
-1.4554
EPS:
-10.1344
Flusso di cassa netto:
$-82.84M
1 W Prestazione:
-19.75%
1M Prestazione:
-35.76%
6M Prestazione:
-52.88%
1 anno Prestazione:
-81.08%
Intervallo 1D:
$14.50
$16.12
Intervallo di 1 settimana:
$14.50
$18.76
Portata 52W:
$14.50
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Nome
Korro Bio Inc
Settore
Industria
Telefono
617-468-1999
Indirizzo
60 FIRST STREET, CAMBRIDGE
Confronta KRRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
14.75 | 138.49M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Raymond James | Strong Buy |
| 2024-08-14 | Iniziato | William Blair | Outperform |
| 2024-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2024-02-27 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-10 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-01-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-10-28 | Iniziato | Cowen | Outperform |
| 2019-10-28 | Iniziato | Goldman | Buy |
| 2019-10-28 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Korro Bio Inc Borsa (KRRO) Ultime notizie
Korro Bio appoints new Chief Scientific Officer By Investing.com - Investing.com South Africa
Korro Bio appoints new Chief Scientific Officer - Investing.com
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - The Manila Times
RNA-Editing Pioneer Korro Bio Lands Elite CSO with 20+ Drug Development Success Record - Stock Titan
Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha
Korro Bio reappoints CFO, names new principal accounting officer By Investing.com - Investing.com Canada
Korro Bio CFO Returns from Medical Leave - TipRanks
Korro Bio reappoints CFO, names new principal accounting officer - Investing.com
Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO - MarketScreener
Research Analysts Set Expectations for Korro Bio Q1 Earnings - Defense World
Q1 Earnings Forecast for Korro Bio Issued By William Blair - Armenian Reporter
HC Wainwright Reiterates Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Q1 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Royal Bank of Canada Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price - Defense World
Korro Bio Reports 2024 Financial Results and Progress - TipRanks
H.C. Wainwright maintains Buy rating on Korro Bio stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy rating on Korro Bio stock - Investing.com
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth - Investing.com Australia
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth By Investing.com - Investing.com South Africa
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo Finance
RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk - Marketscreener.com
Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities - TipRanks
Korro Bio, Inc. SEC 10-K Report - TradingView
Korro Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Korro Bio Reports Clean Safety Data in AATD Drug Trial, Secures $163M Runway - StockTitan
Korro Bio (KRRO) Projected to Post Earnings on Tuesday - Defense World
FDA grants orphan drug status to Korro’s AATD treatment By Investing.com - Investing.com Australia
Korro Bio gets FDA Orphan Drug tag (KRRO:NASDAQ) - Seeking Alpha
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation - Marketscreener.com
FDA grants orphan drug status to Korro’s AATD treatment - Investing.com
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - The Manila Times
Breakthrough for Rare Disease: FDA Awards Special Status to Korro Bio's Novel RNA Treatment - StockTitan
Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
What Will Korro Bio Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World
KRRO stock touches 52-week low at $28.71 amid market challenges - Investing.com Nigeria
Korro Bio CFO takes medical leave, interim officers appointed - MSN
Korro Bio CFO takes medical leave, interim officers appointed By Investing.com - Investing.com Nigeria
Korro Bio Appoints Interim CFO Amid Medical Leave - TipRanks
Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting Officer -February 11, 2025 at 04:05 pm EST - Marketscreener.com
KRRO stock touches 52-week low at $29.8 amid yearly slump - Investing.com
AllianceBernstein L.P.'s Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World
Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World
Korro Bio Inc Azioni (KRRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Korro Bio Inc Azioni (KRRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):